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Background: Glutaric aciduria type I (GA-I) is a rare metabolic disorder caused by inherited deficiency of
glutaryl-CoA dehydrogenase. Despite high prognostic relevance of early diagnosis and start of metabolic treatment
as well as an additional cost saving potential later in life, only a limited number of countries recommend newborn
screening for GA-I. So far only limited data is available enabling health care decision makers to evaluate whether
investing into GA-I screening represents value for money. The aim of our study was therefore to assess the
cost-effectiveness of newborn screening for GA-I by tandem mass spectrometry (MS/MS) compared to a scenario
where GA-I is not included in the MS/MS screening panel.
Methods: We assessed the cost-effectiveness of newborn screening for GA-I against the alternative of not including
GA-I in MS/MS screening. A Markov model was developed simulating the clinical course of screened and
unscreened newborns within different time horizons of 20 and 70 years. Monte Carlo simulation based probabilistic
sensitivity analysis was used to determine the probability of GA-I screening representing a cost-effective
therapeutic strategy.
Results: Within a 20 year time horizon, GA-I screening averts approximately 3.7 DALYs (95% CI 2.9 – 4.5) and about
one life year is gained (95% CI 0.7 – 1.4) per 100,000 neonates screened initially . Moreover, the screening
programme saves a total of around 30,682 Euro (95% CI 14,343 to 49,176 Euro) per 100,000 screened neonates over
a 20 year time horizon.
Conclusion: Within the limitations of the present study, extending pre-existing MS/MS newborn screening
programmes by GA-I represents a highly cost-effective diagnostic strategy when assessed under conditions
comparable to the German health care system.
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Glutaric aciduria type I (GA-I) is a rare genetic disorder
with an estimated prevalence of approximately 1:110,000
in Germany [1] and 1:100,000 worldwide [2]. GA-I is
caused by inherited deficiency of the mitochondrial en-
zyme glutaryl-CoA dehydrogenase (GCDH; EC 1.3.99.7)
which is involved in the final degradative pathways of the* Correspondence: peter.burgard@med.uni-heidelberg.de
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reproduction in any medium, provided the oramino acids L-lysine, L-hydroxylysine, and L-tryptophan.
The majority of newborns with GA-I are asymptomatic,
except for macrocephaly and transient neurological symp-
toms such as axial hypotonia and asymmetric posturing.
Irreversible neurological symptoms generally occur be-
tween the age of three months and three years. Symptoms
may develop acutely during encephalopathic crises precipi-
tated by catabolism or insidiously without such crises [3].
The underlying cause is irreversible striatal injury resulting
in a complex movement disorder with predominant dys-
tonia [4-6]. Previous studies have shown that the outcome. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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childhood [3,7].
Several studies have shown that treatment consisting
of a low lysine diet, carnitine supplementation, and
metabolic emergency treatment during episodes likely
to induce catabolism can significantly reduce mortality
and morbidity in early diagnosed patients [1,8]. This
beneficial therapeutic effect requires early identification
of affected newborns, allowing initiation of treatment in
a clinically presymptomatic state. Newborn screening
for GA-I can be efficiently based on the identification of
elevated glutarylcarnitine (C5DC) concentrations in
dried blood spots by tandem mass spectrometry (MS/
MS). Guidelines have been developed for the diagnosis
and management of GA-I [9,10].
Hence, GA-I fulfills major criteria for the inclusion into
newborn screening programmes [11]. Considering current
national screening panels, GA-I has been recommended as
1 of 29 core panel diseases for newborn screening in the
US and was incorporated into nationwide newborn screen-
ing in Germany in 2005. A European report published
in 2012 indicated that 10 European countries (Austria,
Flemish Belgium, Czech Republic, Denmark, Germany,
Hungary, Iceland, Netherlands, Portugal and Spain) had in-
cluded GA-I into their newborn screening panel [12], while
27 countries did not screen for GA-I. Among these 27
European countries, seven countries (Ireland, Luxemburg,
Norway, Poland, Sweden, Switzerland and the United
Kingdom) were applying MS/MS [13].
A possible reason for this different valuation of new-
born screening for GA-I might be scarce information
regarding its cost-effectiveness. Several previous stud-
ies have analysed the cost effectiveness of introducing
expanded MS/MS newborn screening programmes
for different selections of diseases, including screening
for GA-I [14-17]. A previous review on the cost-
effectiveness of neonatal screening concluded that
screening for GA-I was likely to be highly cost-
effective [18]. At the time this study was performed,
clinical data on the effectiveness of early dietary treat-
ment was limited to a small number of studies, and
management of the disorder was not clearly defined. In
the meantime, several studies have provided further
evidence for the effectiveness of early dietary treatment
[1,3,19]. To our knowledge, the cost-effectiveness for
inclusion of GA-I into pre-existing MS/MS based new-
born screening programmes has never been investi-
gated in detail thereafter, even though it is relevant to
decision makers who want to offer the best “value
for money” to the society [14,20]. The purpose of
our analysis is therefore, to determine the cost-
effectiveness of including GA-I into MS/MS newborn
screening in comparison to the alternative of not in-
cluding GA-I into the screening panel.Methods
Decision analytic modelling
We developed a decision-analytic Markov model to evalu-
ate clinical outcomes for hypothetical cohorts of neonates
who did or did not undergo screening by MS/MS for GA-
I in the newborn period (Figure 1). In health economic
analysis, Markov models are a technique to depict prob-
abilities and time durations for cycles in which individuals
remain in the same or move on to a different health state
[21]. These health states have assigned probabilities, and
values for cost and effectiveness. Cost and effectiveness
are tallied at the end of each cycle and totalled by the end
of the simulation.
We populated our model with published and primary
data and simulated the clinical course of a cohort of
100,000 newborns from birth through ages 20 and 70
years. The subjects in the hypothetical cohort were as-
sumed to make annual transitions between a set of health
states reflecting clinical status and morbidity. Each health
state was associated with an annual cost, an annual effect-
iveness value, and a set of probabilities for subsequent
events. The time spent in each state was used to calculate
life expectancy and costs. We adopted a provider perspec-
tive and followed standard guidelines of economic analysis
[22,23]. Monte-Carlo probabilistic sensitivity analysis [24]
was used to assess the probability of the alternative treat-
ment strategies being cost-effective, thereby enabling to
determine the robustness of our results. As this study was
not experimental and did not include research carried out
on humans ethical approval was not necessary.
Strategies
We modelled two competing scenarios (Figure 1). In the
first scenario, newborns do not undergo universal GA-I
screening. Individuals either have or do not have the dis-
order. Unscreened infants without the disorder are and
remain unaffected infants. Unscreened infants with the
disorder can be in one out of four health states: undiag-
nosed GA-I, asymptomatic diagnosed GA-I, permanent
impairment due to GA-I, or death. “Undiagnosed” repre-
sents individuals who have the disorder but who are so far
clinically unaffected and thus undiagnosed. “Asymptom-
atic diagnosed” represents individuals who have the dis-
order and were diagnosed either due to macrocephaly, by
clinical signs including acute encephalopathy or by high-
risk screening, but do not suffer from severe permanent
impairment defined as severe movement disorder (sMD).
Importantly, the “asymptomatic” state also includes per-
sons with milder movement disorders, as these persons
usually are not significantly disabled in daily life activities
[1]. “Permanent impairment” thus subsumes all individ-
uals who are affected by sMD due to GA-I. This health
state is associated with significantly higher cost and higher
mortality risk compared to the “asymptomatic” health
Figure 1 (See legend on next page.)
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Figure 1 Markov Model to assess the cost-effectiveness of MS/MS-based neonatal screening for GA-I. Following the initial screening
decision, GA-I can be diagnosed either based on the screening result, based on the clinical sign of macrocephaly (early diagnosis) or following an
acute encephalopathic crisis (diagnosis on clinical sign). Regarding the health state, individuals with GA-I can either be healthy or have only mild
symptoms (asymptomatic diagnosed), suffer from severe movement disorder (impaired), or have died (death). Healthy individuals with GA-I in
whom the diagnosis has not been established (undiagnosed) have a higher risk to experience acute encephalopathic crisis than healthy children
with known diagnosis (asymptomatic diagnosed).
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GA-I-related or from other causes.
The second scenario offers newborn screening for GA-I,
where neonates can test either positive or negative. We as-
sume that testing is based on current guidelines [10], and
that positive newborn screening, including positive con-
firmatory test results, establishes the diagnosis of GA-I
with perfect specificity. However, it is known that false
negative screening results occur and thus, baseline analysis
included a test sensitivity of 94.5% [1] and was subject to
further sensitivity analysis. Following the definitions above,
individuals with a confirmed diagnosis of GA-I can be in
the health states “asymptomatic”, “impaired” or “death”.
Incremental cost-effectiveness ratios (ICER) were cal-
culated under the assumption that MS/MS had already
been introduced for newborn screening. Therefore, only
variable costs of adding screening for GA-I are included
in the analysis. Our calculations of the true ICER for
universal screening for GA-I are conservative as we con-
sidered the upper bound when estimating costs, and the
lower bound when estimating health outcomes associ-
ated with the screening strategy. In the non-screening
scenario we considered the lower bound of costs and the
upper bound of health outcomes.
Thus, the reported cost-effectiveness ratios for univer-
sal neonatal GA-I screening are likely to be upper-end
estimates, following standard guidelines of economic
cost-effectiveness analysis [22,25]. Cost and effectiveness
were discounted at an annual rate of 3% and calculated
for two time horizons of either 20 or 70 years, in accord-
ance with the time horizon considered in a previously
published cost-effectiveness analysis for medium-chain
acyl-CoA dehydrogenase deficiency screening [26].
Data sources
Data and data sources used in the model are shown in
Table 1. Sources of data included previous publications on
the outcome in GA-I following either clinical diagnosis or
newborn screening. Data was supplemented by primary
data of a 10-year prospective follow-up study performed
at our study centre [27], as well as expert clinical opinion
from the authors SK and ML (assumptions).
Course of disease
If newborn screening for GA-I is not established, GA-I
patients can be diagnosed either early due to clinicalsigns like macrocephaly, a known index case in an af-
fected family, or after the manifestation of irreversible
neurologic symptoms (e.g. complex movement disorder).
In the scenario without newborn screening for GA-I,
we assumed that diagnosis based on high-risk screening
of macrocephaly is established in 15% of cases, while the
other 85% of cases will be diagnosed after clinical pres-
entation. These figures were derived from a previous re-
port of a total of 279 patients. Among these, 23 were
diagnosed by neonatal screening while of the remaining
256 individuals, 24 were diagnosed by high-risk screen-
ing, 14 by macrocephaly (combined 38/256 = 14.8%) and
218 individuals (218/256 = 85.2%) were detected after
clinical presentation [3].
For infants being diagnosed early on the basis of high-
risk screening, we assumed the clinical course to be
identical to the cohort undergoing newborn screening.
In cases where diagnosis is made following (non-macro-
cephalic) clinical presentation, we assumed 74% to suffer
from sMD [28].
The scenario presenting a universal neonatal screening
for GA-I includes 11.5% of the diagnosed cases to suffer
from sMD. Even though consequent basic and emergency
treatment may lead to a better outcome, 11.5% is a conser-
vative estimate regarding the possibility of insufficient
treatment as previously reported [1]. For false negative
screening results, the course of disease was assumed to be
equal to the outcome of the previously described strategy
without universal neonatal screening.
Mortality in the asymptomatic health state was as-
sumed to be equal to the healthy population as reported
in the official German mortality table in 2009 [29].
For children affected by severe movement disorder, it
has been reported that as many as 50% die before the age
of 25 years, often due to severe aspiration pneumonia [3].
Considering likely improvement of current treatment op-
tions, we estimated a mean life expectancy of 35 years for
individuals in the “impaired” health state for base case
analysis and included this estimate into sensitivity analysis.
Cost assessment
The GA-I screening process includes the initial MS/
MS-based newborn screening cost (direct screening
cost), and in case of a positive test result confirmation
testing, including metabolites, enzyme activity and mu-
tation analysis.
Table 1 Effectiveness and cost input variables used in the analysis
Distribution Distribution parameters Data source
Epidemiology, prevalence and effectiveness Base case
Test Specificity (including confirmation by enzyme analysis) Point estimate 1 Assumption
Test Sensitivity Triangular Mode 0.945 (min-max 0.9-0.99) [1,3]
Prevalence based on positive test result Triangular Mode: 1 in 112,700, (min-max
1 in 129,455 – 1 in 95,953)
[1]
Probability of early diagnosis before the onset of sMD Triangular Mode 0.15 (min-max 0.12-0.18) [3]
Probability that severe movement disorder develops
in previously diagnosed children
Triangular Mode 0.115 (min-max 0.092-0.138) [1]
Probability that severe movement disorder occur
following clinical manifestation
Triangular Mode 0.74 (min-max 0.592-0.888) [28]
Life expectancy of healthy population Point estimate 79.45 years [29]
Life expectancy in asymptomatic persons with GA-I Equal to life expectancy
of healthy population
Assumption
Life expectancy in impaired health state Uniform Min-max 25–45 years [3]
Cost Assessment
A) Direct screening cost, including genetic and
enzymatic confirmation studies
Initial medical cost for children experiencing
an acute encephalopathic crisis
Triangular Mode 3000 (min-max 2000–8000) Assumption, based on year 2010
German DRG reimbursement
Cost for genetic and enzymatic confirmation studies Point estimate 865 Primary data
Direct screening cost per neonate Point estimate 0.031 Calculated, based on [30]
B) Cost for medical and dietary treatment in
persons with GA-l
Cost per outpatient visit Triangular Mode 127 (min-max 88.9 -165.1) Primary data
Cost per inpatient treatment Triangular Mode 1335 (min-max 934.5 - 1735.5) Primary data
Number of outpatient treatments per year Point estimate Age-depending [10]
Number of inpatient treatments per year Point estimate Age-depending [10]
Cost for basic dietary treatment per year Point estimate Age-depending [10]
C) Cost associated with severe movement
disorder
Annual cost for special schooling (included for age 6 to 16) Triangular Mode 5689 (min-max 0–11369) Assumption, based on [31]
Annual cost for special care, starting after age of 6 Triangular Mode 2700 (min-max 1890–3510) Assumption, based on [32]
Annual overhead cost in case of severe movement disorder Uniform Min-max 0-3000 Assumption
All costs are expressed in Euro for the year 2010.
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been established for newborn screening. In this case, ex-
tension of the pre-existing screening by GA-I will cause
only minimal additional cost, since C5DC is only one of
many acylcarnitines which are detectable using the same
analytical process, i.e. MS/MS. We conservatively assumed
that the inclusion of GA-I would lead to an additional re-
call rate of 0.08%, corresponding to the total recall rate in
the German screening panel for all screened diseases by
MS/MS with exclusion of phenylketonuria and medium
chain acyl-dehydrogenase deficiency. A recall will cause a
cost of 31.01 Euro for clinical examination of the newborn
and taking a new blood sample by a physician plus 7.00
Euro for repeated MS/MS analysis [33].
We thereby calculated that inclusion of GA-I into the
already established MS/MS-based newborn screening
panel would result in an additional cost of 0.031 Euro
per neonate. However, this value only reflects the cost of
GA-I screening for a scenario with a pre-existing MS/
MS newborn screening programme. In a situation where
MS/MS screening is performed only for a limited num-
ber of target conditions, inclusion of GA-I in the screen-
ing panel might necessitate resourcing of additional
internal standards for acylcarnitines and thereby cause
additional screening costs. Furthermore, in a scenario
where newborn screening is based on another (non MS/
MS) screening technology, inclusion of GA-I into the
screening panel will require the introduction of MS/MS
technology, possibly resulting in a considerably higher
marginal screening cost per newborn. We applied one-
way sensitivity analysis to assess the influence of screen-
ing cost on the ICER of GA-I newborn screening.
Following a positive screening result, the diagnosis of
GA-I is confirmed by metabolite, mutation analysis and/or
enzyme activity. The cost of these tests is 25, 800 and 800
Euro, respectively. In current practice, mutation analysis is
usually done prior to enzyme activity. Mutation analysis
has a sensitivity of around 98%, and only in unclear cases
enzyme activity is determined. For this study, we assume
that enzyme activity is required in 5% of children with a
positive MS/MS screening result, leading to a total cost of
865 (=25+800+0.05*800) Euro.
For children in whom the diagnosis of GA-I is based on
clinical symptoms (complex movement disorder with pre-
dominant dystonia), we estimated a total cost of 3,000
Euro, including possible inpatient treatment and confirm-
ation analysis. This assumption might underestimate the
true costs as some children will probably undergo several
tests and hospital stays before the diagnosis can be made,
but is in line with the conservative assumption for the cost
of the scenario without universal newborn screening.
We further assumed that all infants diagnosed with
GA-I receive treatment according to current guidelines
[10]. This dietary treatment includes a low lysine dietusing natural food with low lysine content and lysine-
free amino acid supplements during the first six years of
life. The amount of lysine-free amino acid supplements
is dependent on the individual diet. We assumed that on
average, 40% of the daily amino acid intake would be
covered by lysine-free amino acid supplements. We add-
itionally considered the cost of levocarnitine substitution
(100 mg/kg/d for the first six years of life, followed by
30 mg/kg/d for lifetime).
In addition to dietary treatment, the cost for out- and in-
patient treatment due to GA-I was accounted for in all di-
agnosed persons. The frequency of such interventions was
based on current treatment recommendations [10], while
the cost per in- or outpatient treatment was calculated on
the basis of the general diagnosis-related group (DRG) re-
imbursement system in Germany in the year 2010.
For children affected by sMD, additional costs includ-
ing special care and schooling were considered in the
model. It is very likely that severely affected individuals
will require a higher frequency of medical interventions.
However, we did not have sufficient data to assess these
costs as only very few children in our study cohort suffer
from severe movement disorder. Thus, in our model the
same frequency of in- and outpatient treatment was
assigned to individuals in the impaired health state and
asymptomatic individuals. As this approach is very likely
to underestimate the true costs in the impaired health
state, sensitivity analysis included analysis of an overhead
lump sum assigned to the impaired state. Table 1 shows
key input parameters of the model. All costs were calcu-
lated in Euros for the year 2010.
Effectiveness
The primary measure of clinical outcome was the number
of Disability Adjusted Life Years (DALYs) in each of the
treatment arms. DALYs is a measurement of overall dis-
ease burden, combining the expected years of life lost be-
cause of reduced life expectancy with years lived with
disability [34]. In our analysis, using DALYs as primary
measure of screening effectiveness thereby accounts for
both, life years lost due to early mortality as well as for life
years with disability caused by sMD. In general, one DALY
is equal to one year of healthy life lost. In order to calcu-
late DALYs, disability weights are used to reflect the sever-
ity of a health state on a scale from 0 (perfect health) to 1
(equivalent to death). In the absence of an established dis-
ability weight for children suffering from sMD, we had to
make an estimate on a disability weight that could ad-
equately reflect the impact of severe sMD. Among the dis-
ability weights for diseases and conditions published by
the WHO [35,36], we found that the disability weight for
mental retardation following meningitis (disability weight
of 0.459, range 0.402 to 0.484) and the disability weight for
neurological sequelae following cerebral malaria (0.471,
Table 3 Incremental cost of universal GA-I newborn
screening per 100,000 neonates
Mean value 95% CI
Incremental cost,
20 years horizon
−30,682 € −14,550 € to −49,401 €
Incremental cost,
70 years horizon
−36,743 € −19,072 € to −57,365 €
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sMD. Common features of neurological sequelae following
cerebral malaria in children include hemiplegia, cortical
blindness, aphasia and ataxia [37], while hearing loss, men-
tal retardation, motor abnormalities and seizures are com-
mon neurological sequelae following bacterial meningitis
[38]. For our primary analysis, we approximated the impact
of sMD by using the published disability weight of neuro-
logical sequelae following malaria infection.
As secondary effectiveness measure, we considered the
number of average life years gained when comparing
screening vs. not screening. The sum of the annual cycles
spent in all states other than death represented average life
expectancy of members of the cohort. Age weighting was
not applied, thus a year of healthy life was valued equally
at all ages.Sensitivity analysis
To assess the uncertainty in the model and the robust-
ness of our results, we used one-way sensitivity analysis
and Monte Carlo probabilistic sensitivity analysis. One-
way sensitivity analysis assesses the influence of single
parameters on a result. Monte-Carlo probabilistic sensi-
tivity analysis (50,000 repetitions) simultaneously varied
input variables over their full range (Table 1).Results and discussion
Table 2 shows the predicted effectiveness of newborn
screening for GA-I. For a 20 years horizon, the screening
programme averts approximately 3.7 DALYs (95% CI 2.9 –
4.5) and about 1.0 life year will be gained (95% CI 0.7 – 1.4)
per 100,000 neonates screened initially. When followed for
70 years, 4.1 life years (95% CI 3.0 – 5.7) in a cohort of
100,000 screened neonates and a total of 6.0 DALYs (95%
CI 4.7 – 7.5) are averted by GA-I newborn screening.
Extension of a pre-existing MS/MS newborn screening
programme by GA-I saves a total of approximately 30,682
Euro (95% CI 14,343 to 49,176) and 36,743 Euro (95% CI
20,178 to 58,531) per 100,000 screened neonates over the
20 and 70 year time horizon, respectively (Table 3). Thus,
the strategy with newborn screening for GA-I is more ef-
fective, as well as cost saving compared to the strategy with-
out screening for a 20, as well as for a 70 year horizon.Table 2 Predicted effectiveness of the screening
programme per 100,000 neonates
20 years horizon Mean value 95% CI
Life years gained 1.0 0.7 – 1.4
DALY averted 3.7 2.9 – 4.5
70 years horizon Mean value 95% CI
Life years gained 4.1 3.0 – 5.7
DALY averted 6.0 4.7 – 7.5One-way sensitivity analysis was used to further assess
the influence of single input parameters on the model out-
come. Input parameters were assessed according to
Table 1, and all results showed that the strategy with new-
born screening remained the dominant, i.e. cost-saving
intervention (data not shown).
As GA-I is a rare metabolic disorder, we expected that
the cost for the initial screening, which is attributable to
all newborns, would be a critical parameter in the cost-
effectiveness evaluation of the GA-I screening programme.
This is of special importance as the incremental cost of
neonatal GA-I screening is dependent on the screening
programme already available. Our analysis considers a sce-
nario where MS/MS screening for the whole range of
acylcarnitines is already established and extended to a
wider range of target conditions. In such a scenario, the
incremental cost of GA-I screening might be negligible. In
contrast, in a scenario where MS/MS screening is pre-
established but includes only a limited number of target
conditions (e.g. representing the current screening prac-
tice in the UK), inclusion of GA-I in the screening panel
might require the introduction of additional internal stan-
dards for acylcarnitines and would thereby result in an in-
cremental cost of about 0.2 to 0.3 Euros per neonate [39].
Figure 2 illustrates the ICER of the screening versus the
non-screening scenario at different values of the initial
screening cost at a 20 years horizon. Inclusion of GA-I
into the newborn screening panel was found to be cost
saving if the screening cost was below 0.34 Euro per ini-
tially screened neonate. At a higher screening cost, the
strategy with GA-I screening is expected to be more
expensive than the strategy without screening. At a cost of
e.g. 1.07 Euro per neonate, GA-I screening results in an
incremental cost-effectiveness of 20,000 Euro per DALY
averted. Thus, inclusion of GA-I screening into a pre-
existing MS/MS based screening panel remains a cost sav-
ing intervention even in a scenario where additional
internal standards for acylcarnitines are required. For other
countries widely differing prevalence rates for GA-I,
ranging from 1 in 35000 in Spain [40] to 1 in 354000 in
California [41] have been reported. We assessed the impact
of these prevalence rates on cost and cost-effectiveness esti-
mates in an independent analysis for a 20 years horizon at
incremental screening costs of 0.03 and 0.3 Euros per neo-
nate, reflecting a scenario with or without pre-established
GA-I acylcarnitine internal standards, respectively.
Figure 2 ICER (In EURO per DALY averted) depending on the initial cost of GA-I screening (direct cost of GA-I screening, in EURO per
newborn over a 20 year horizon).
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an existing MS/MS screening programme by GA-I re-
mains a cost-saving intervention at any prevalence
assessed. Assuming an incremental screening cost of 0.3
Euro per neonate, the intervention ceases to be cost-
saving at a prevalence of 1 in 200,000, with a resulting
ICER of approximately 5,700 Euro (95% CI 651 –
10,728) per DALY averted (Table 4). It is important to
note, that these findings are based on the cost assump-
tions reported in Table 1.
The WHO Commission on Macroeconomics and
Health classified interventions as highly cost effective if
the cost per DALY averted was less than the gross domes-
tic product (GDP) per head, and as cost effective if this
cost was less than one-to-three times the GDP per head.
With the 2010 per capita GDP of $ 38,170 for Germany
and $ 34,177 for the Euro area (adjusted for purchasing
power parity and expressed in international dollars) as a
threshold [42], inclusion of GA-I into MS/MS newborn
screening programmes is a highly cost effective health
intervention according to our study results.
In a scenario without pre-existing MS/MS newborn
screening, introduction of GA-I screening necessitatesTable 4 Cost and cost-effectiveness of universal GA-I newborn
high incremental screening cost
Incremental screening cost 0.03 Euro/neonate
Prevalence Mean incremental cost per
100000 screened neonates (95% CI)
ICER
1 in 35,000 −103,445 (−160,339 – -52,919) <0
1 in 100,000 −34,191 (−54,104 – -16,507) <0
1 in 200,000 −15,545 (−25,502 – -6,703) <0
1 in 350,000 −7,555 (− 13,244 – - 2,502) <0
All values in Euro, 20 years horizon.a change of screening technology. In this case, the in-
cremental cost of GA-I screening might widely differ
from our baseline assumptions and furthermore, not
only GA-I, but also other conditions, even those hith-
erto screened for by other methodology, could be in-
cluded in the screening panel with the change of
screening methodology. Our analysis was not designed
to assess the economic consequences of such a scenario.
Several previous studies have evaluated the cost-
effectiveness of introducing MS/MS newborn screening,
reporting that MS/MS screening for a combination of
different diseases is attractive from an economic per-
spective [15-18,43].
Regarding generalizability of our findings, some con-
cern may be that these results would only be valid under
the conditions of the German health system. This ap-
plies especially to the estimation of cost, as the precise
costs we incorporated in our decision analytic model
can, of course, only be considered fully reliable for the
specific scenario assumed. In contrast, the clinical evi-
dence that our study is based on is not restricted to a
single geographic setting but is derived from a variety of
European countries and Australia [1,7,28,44,45].screening at differing prevalence rates and low versus
Incremental screening cost 0.3 Euro/neonate
Mean incremental cost per
100000 screened neonates (95% CI)
ICER (95% CI)
−76,545 (−133,439 – -26,019) <0
−7,291 (−27,204 – 10,393) −1,750 (−6,417 - 2,657)
11,355 (1,398 – 20,197) 5,703 (651 – 10,728)
19,345 (13,656 – 24,398) 16,882 (10,800 – 23,491)
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showed that, with exception of the initial screening cost,
our results are robust for all relevant input parameters
and the scenario with universal GA-I screening remained
cost saving in all analyses at a 20, as well as a 70 year hori-
zon. Therefore, it is reasonable to assume that inclusion of
GA-I into the newborn screening panel will be a highly
cost-effective health intervention not only in Germany,
but also in many other countries with similar health and
welfare systems.
We used DALYs as primary outcome measure, while
recent health economic evaluations of neonatal medium
chain acyl-CoA dehydrogenase deficiency (MCADD)
reported quality adjusted life years (QALYs) [46,47].
Both, QALYs and DALYs, are measures of disease bur-
den allowing to combine morbidity and mortality in a
single outcome measure [48]. QALYs are derived by as-
sessment of health states using different methods like
time-trade-off, visual analogue scales or standard de-
scriptive systems like the EuroQuol EQ5D questionnaire
[49]. In contrast, DALYs rely on disability weights asso-
ciated with specific diseases (rather than health states),
and they are usually derived through expert opinion.
Groups of experts rated the severity of disabling seque-
lae initially according to six disability classes [34] or in a
revised version by 22 indicator conditions [50]. It is evi-
dent that all available outcome measures for health eco-
nomic evaluations have their strengths and limitations
[48,51]. Regarding the DALY concept, major points of
criticism are the exclusion of the patient’s health percep-
tion as well as the living circumstances of individuals who
experience morbidity [52]. In contrast, regarding QALYs,
it has been discussed that measuring the health status of
children raises important methodological issues like the
age-dependency of health perception as well as the influ-
ence of parents [53]. Moreover, the QALY concept has
been criticised for an overall lack of quality in paediatric
care [54]. Regarding the present analysis, no suitable data
was available for calculating QALYs according to meth-
odological standards. Furthermore, self-assessment or the
use of time-trade-off techniques seems unfeasible in chil-
dren suffering from severe impairments [55]. We therefore
made an expert assumption among the study authors to
derive an appropriate disability weight for our analysis.
We felt that the evidence level is best reflected by using
DALYs for health outcome measurement. Despite the fact
that there may always be additional information gained
from health economic evaluation, it is pivotal to be aware
of the limitations implied by the particular method used,
especially when only one specific health outcome measure
(e.g. DALYs) is feasible for application. As there is no well-
established disability weighting for inherited metabolic
disorders, cost-effectiveness analysis should only be one
among several aspects in decision making. For futurehealth economic assessment, it would be desirable to
establish a broader consensus on appropriate outcome
measurement.
A final general concern regarding our analysis is the
extent and quality of available evidence which our analysis
is based on. Current knowledge of the clinical course of
GA-I is based on a relatively small number of studies
[1,7,28,44,45]. In addition, sample sizes of these studies
may be regarded as comparably small. Therefore, our re-
sults indicate considerable uncertainty and should thus be
interpreted with caution. It is of special concern that the
natural course and outcome of screened and unscreened
individuals with GA-I was derived from previously pub-
lished studies [1,3,28]. In these historical cohorts, un-
screened individuals were born earlier, i.e. before
introduction of MS/MS based screening for GA-I. There-
fore, the superior outcome of screened individuals might
not only be attributable to the screening itself, but also to
other, time-dependant improvements in health care. In
contrast, it is possible that prior to the introduction of
newborn screening for GA-I, a significant amount of chil-
dren suffering from GA-I might have deceased without
the diagnosis being established. Thus, the reported data
might both, over- as well as underestimate GA-I related
morbidity and mortality in unscreened individuals.
The availability of limited clinical data is a constraint
which applies to any rare disease. In these situations the
only choice is to base decisions about cost-effectiveness on
the currently available evidence and to use uncertainties for
determining domains where further research is needed [56].
Introduction of large-scale, multi-national databases for pa-
tients with rare metabolic diseases might be a useful tool to
provide more detailed information on the clinical course of
patients with rare metabolic disorders, e.g. the European
registry and network for intoxication type metabolic disor-
ders [56] (https://www.eimd-registry.org/).
Conclusion
In line with current evidence, our findings indicate that
the morbidity resulting from GA-I can be considerably
reduced by early diagnosis and treatment. Moreover, the
long-term costs of screening for GA-I were shown to be
lower than excluding GA-I from a MS/MS screening
panel. To extend a pre-existing MS/MS screening by
GA-I is a cost saving health intervention under condi-
tions comparable to the German health system. Our
findings may also apply to other countries with similar
health and welfare systems. The inclusion of GA-I into
newborn screening programmes merits serious consider-
ation by health policy makers.
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